Apr 1, 2022 · Here, we report the development of DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a potent DNA topoisomerase I inhibitor, and its in vitro profile, pharmacokinetic profiles, safety profiles, and in vivo antitumor activities in nonclinical species.

Jan 13, 2024 · 1月12日，clinicaltrials.gov网站显示，第一三共启动了DS-7300（ifinatamab deruxtecan，I-DXd）的III期临床试验（IDeate-2）。 该药物是首款进入III期阶段的B7H3 ADC。 I-DXd是第一三共基于其DXd ADC技术平台开发的一款B7H3 ADC，也是与HER3-DXd（HER3 ADC）和R-DXd（CDH6 ADC）同为默沙东参与 ...

本文主要介绍笔者看来最有希望的治疗药物， ds-7300 ，也称为 i-dxd 。 这是一个adc类的药物，抗体部分的靶点是 b7-h3 ，毒素部分用的是和 ds-8201 相同的dxd。 作为都是第一三共的研发产品，使用同一adc平台开发出了一系列的潜在重磅adc。

DS-7300 is an antibody-drug conjugate (ADC) composed of a humanized anti–B7- H3 immunoglobulin G1 (IgG1) monoclonal antibody conjugated to a drug linker that releases its payload ( DXd) upon internalization by cancer cells

Oct 25, 2022 · 验，旨在评估治疗广泛期小细胞肺癌（SCLC）患者中的疗效和安全性。DS-7300 是由第一三共研发的B7-H3 靶向的潜在first-in-class 的抗体偶联药物（ADC）。 肺癌是全球第二大常见癌症，死亡率也一直居高不下。在中国约15%的患者被

Sep 10, 2022 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-7300 is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) …

Apr 1, 2022 · DS-7300a is designed to bind to B7-H3 on the cell surface; upon binding, it is internalized into cancer cells and releases its DXd in cytoplasm after its linker is being cleaved with enzymatic processing. The released DXd inhibits TOP1 activity and leads to the apoptosis of target cancer cells.

This global phase 2 trial is evaluating the efficacy and safety of two doses (8 mg/kg or 12 mg/kg) of DS-7300 in patients with histologically or cytologically confirmed extensive-stage SCLC that received at least one prior line of platinum-based chemotherapy. Patients will be randomized 1:1 to receive either 8 mg/kg or 12 mg/kg of DS-7300.

DS-7300 is an investigational B7-H3 directed ADC and is one of six ADCs currently in clinical development in the oncology pipeline of Daiichi Sankyo. Designed using Daiichi Sankyo’s proprietary DXd ADC

Nov 4, 2019 · ds-7300是一种b7-h3靶向抗体药物偶联物（adc），目前正开发用于接受标准疗法治疗后病情进展或无标准治疗方案的各种晚期实体瘤患者。 B7-H3（B7 ...